2009 Santa Fe Bone symposium.
Osteoporosis is a common skeletal disease with serious clinical consequences because of fractures. Despite the availability of clinical tools to diagnose osteoporosis and assess fracture risk, and drugs proven to reduce fracture risk, it remains a disease that is underdiagnosed and undertreated. When treatment is started, it is commonly not taken correctly or long enough to be effective. Recent advances in understanding of the regulators and mediators of bone remodeling have led to new therapeutic targets and the development of drugs that may offer advantages over current agents in reducing the burden of osteoporotic fractures. Many genetic factors that play a role in the pathogenesis of osteoporosis and metabolic bone disease have now been identified. At the 2009 Santa Fe Bone Symposium, held in Santa Fe, New Mexico, USA, the links between advances in genetics, basic bone science, recent clinical trials, and new and emerging therapeutic agents were presented and explored. Socioeconomic challenges and opportunities in the care of osteoporosis were discussed. This is a collection of medical essays based on key presentations at the 2009 Santa Fe Bone Symposium.
Lewiecki
E Michael
EM
New Mexico Clinical Research & Osteoporosis Center, Albuquerque, NM, USA. Electronic address: lewiecki@aol.com.
Bilezikian
John P
JP
Columbia University College of Physicians and Surgeons, NYC, NY, USA.
Laster
Andrew J
AJ
Arthritis and Osteoporosis Consultants of the Carolinas, Charlotte, NC, USA.
Miller
Paul D
PD
Colorado Center for Bone Research, Lakewood, CO, USA.
Recker
Robert R
RR
Creighton University School of Medicine, Omaha, NE, USA.
Russell
R Graham G
RGG
The Botnar Research Centre, University of Oxford, Oxford, UK.
Whyte
Michael P
MP
Washington University School of Medicine, St. Louis, MO, USA.
D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D016723:Bone Remodeling / Q000187:drug effects*; D003226:Congresses as Topic; D050723:Fractures, Bone / Q000209:etiology / Q000517:prevention & control; D006801:Humans; D009516:New Mexico; D010024:Osteoporosis / Q000150:complications / Q000188:drug therapy*
D050071:Bone Density Conservation Agents